Delivery of adenoviruses encoding antiangiogenic factors (pigment epithelium-derived factor and endostatin) synergized with cytokines (GM-CSF and IL-12) to induce an significant therapeutic effect against hepatocellular carcinoma by reducing immune tolerance and making tumor more vulnerable to the immune reactions [15]. This evidence concerns the gene COL18A1 and hepatocellular carcinoma.